The risk of bleeding, as well as patient preferences, must be considered when deciding duration of warfarin therapy
Venous thromboembolism (VTE) affects about 17 000 Australians each year, usually as deep vein thrombosis (DVT) of the legs or pulmonary embolism (PE).1 The sequelae of VTE include death, post-thrombotic syndrome, chronic pulmonary thromboembolic disease and recurrent VTE. Anticoagulation with an oral vitamin K antagonist (warfarin), overlapped for the first 5–7 days with unfractionated heparin, low-molecular-weight heparin or fondaparinux, prevents thrombus progression and reduces the risk of recurrent VTE and death during the acute phase.2,3 When treatment is continued beyond the acute phase, warfarin reduces the risk of recurrent VTE but increases the risk of bleeding and requires frequent laboratory monitoring, which is inconvenient for patients. Thus, decisions regarding the optimal duration of anticoagulant therapy must balance the increased risk and sequelae of recurrent VTE when warfarin is stopped against the risk of bleeding and the inconvenience of continuing treatment.3
The full article is accessible to AMA members and paid subscribers. Login to read more or purchase a subscription now.
Please note: institutional and Research4Life access to the MJA is now provided through Wiley Online Library.
- 1 Department of Medicine, McMaster University, Hamilton, Ontario, Canada.
- 2 Thrombosis Service, McMaster Clinic, Hamilton, Ontario, Canada.
- 1. Ho WK, Hankey GJ, Eikelboom JW. The incidence of venous thromboembolism: a prospective, community-based study in Perth, Western Australia. Med J Aust 2008; 189: 144-147. <MJA full text>
- 2. Ho WK, Hankey GJ, Lee CH, Eikelboom JW. Venous thromboembolism: diagnosis and management of deep venous thrombosis. Med J Aust 2005; 182: 476-481. <MJA full text>
- 3. Lee CH, Hankey GJ, Ho WK, Eikelboom JW. Venous thromboembolism: diagnosis and management of pulmonary embolism. Med J Aust 2005; 182: 569-574. <MJA full text>
- 4. Kearon C, Ginsberg JS, Anderson DR, et al. Comparison of 1 month with 3 months of anticoagulation for a first episode of venous thromboembolism associated with a transient risk factor. J Thromb Haemost 2004; 2: 743-749.
- 5. Pinede L, Ninet J, Duhaut P, et al; Investigators of the Durée Optimale du Treatment AntiVitamines K (DOTAVK) Study. Comparison of 3 and 6 months of oral anticoagulant therapy after a first episode of proximal deep vein thrombosis or pulmonary embolism and comparison of 6 and 12 weeks of therapy after isolated calf deep vein thrombosis. Circulation 2001; 103: 2453-2460.
- 6. Campbell IA, Bentley DP, Prescott RJ, et al. Anticoagulation for three versus six months in patients with deep vein thrombosis or pulmonary embolism, or both: randomised trial. BMJ 2007; 334: 674.
- 7. Pinede L, Duhaut P, Cucherat M, et al. Comparison of long versus short duration of anticoagulant therapy after a first episode of venous thromboembolism: a meta-analysis of randomized, controlled trials. J Intern Med 2000; 247: 553-562.
- 8. Ost D, Tepper J, Mihara H, et al. Duration of anticoagulation following venous thromboembolism: a meta-analysis. JAMA 2005; 294: 706-715.
- 9. Agnelli G, Prandoni P, Santamaria MG, et al. Three months versus one year of oral anticoagulation therapy for idiopathic deep vein thrombosis. Warfarin Optimal Duration Italian Trial Investigators. N Engl J Med 2001; 345: 165-169.
- 10. Hutten BA, Prins MH. Duration of treatment with vitamin K antagonists in symptomatic venous thromboembolism. Cochrane Database Syst Rev 2006; (1): CD001367.
- 11. Linkins LA, Choi PT, Douketis J. Clinical impact of bleeding in patients taking oral anticoagulant therapy for venous thromboembolism. Ann Intern Med 2003; 139: 893-900.
- 12. Kearon C, Ginsberg JS, Kovacs MJ, et al; Extended Low-Intensity Anticoagulation for Thrombo-Embolism Investigators. Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism. N Engl J Med 2003; 349: 631-639.
- 13. Verma AK, Brighton TA. The direct factor Xa inhibitor rivaroxaban. Med J Aust 2009; 190: 379-383. <MJA full text>
- 14. Kearon C, Kahn S, Agnelli G, et al. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Chest 2008; 133 (6 Suppl): 454S-545S.